CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Veloxis Pharmaceuticals AS is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Veloxis Pharmaceuticals AS
c/o Plesner Advokatpartnerselskab
Amerika Plads 37, Koebenhavn Oe
Phone: +45 70333300p:+45 70333300 Koebenhavn, 2100  Denmark Fax: +45 36130319f:+45 36130319

This company is no longer actively traded on any major stock exchange.

Business Summary
Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a Denmark-based commercial-stage specialty pharmaceutical company. The Company operates in the United States (US) through its subsidiary, Veloxis Pharmaceuticals Inc, based in Cary, North Carolina, US. The Company’s products include: Envarsus XR (tacrolimus extended-release tablets), a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant, as well as Fenoglide for the treatment of dyslipidemia in the United States. Envarsus XR is based upon the Company's patented delivery technology, MeltDose, which is designed to help the absorption and bioavailability of select orally administered drugs.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Michael T.Heffernan 54 4/6/2016 3/26/2015
President, Chief Executive Officer Craig A.Collard 9/24/2018 12/10/2015
Independent Deputy Chairman of the Board Mette K.Agger 56 4/6/2016 4/21/2010
10 additional Officers and Directors records available in full report.

Business Names
Business Name
0IVI
L8H
LCP
LifeCycle Pharma A/S
VELO
VOXPY

General Information
Number of Employees: 60 (As of 9/30/2019)
Outstanding Shares: 1,739,741,590 (As of 12/20/2019)
Shareholders: 8,723
Stock Exchange: CPH
Fax Number: +45 36130319


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, July 23, 2023